Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-1801
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy ; volume:5 ; number:1 ; day:3 ; month:11 ; year:2016 ; pages:1-8 ; date:12.2016
SpringerPlus ; 5, Heft 1 (3.11.2016), 1-8, 12.2016
- Creator
-
Ha, Sang Ook
- Contributor
-
Kim, Hyoung Soo
Park, Sunghoon
Jung, Ki-Suck
Jang, Seung Hun
Han, Sang Jin
Kim, Hyun-Sook
Lee, Sun Hee
SpringerLink (Online service)
- DOI
-
10.1186/s40064-016-3571-9
- URN
-
urn:nbn:de:1111-2016112811361
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ha, Sang Ook
- Kim, Hyoung Soo
- Park, Sunghoon
- Jung, Ki-Suck
- Jang, Seung Hun
- Han, Sang Jin
- Kim, Hyun-Sook
- Lee, Sun Hee
- SpringerLink (Online service)
Other Objects (12)
Optimierung der ECMO-Therapie bei schwerem ARDS
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
The initiation of adenovirus DNA replication
To prone or not to prone ARDS patients on ECMO
Hämolyse bei Patientinnen und Patienten mit ARDS und Therapie mit ECMO
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Use of ECMO in ARDS: does the EOLIA trial really help?
ECMO is associated with decreased hospital mortality in COVID-19 ARDS
Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
Mesenchymal stem cells-based therapies for severe ARDS with ECMO: a review
Influenza-A/H1N1-Infektion – Welchen Nutzen hat eine ECMO bei schwerem ARDS?
Optimierung der ECMO-Therapie bei schwerem ARDS
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
The initiation of adenovirus DNA replication
To prone or not to prone ARDS patients on ECMO
Hämolyse bei Patientinnen und Patienten mit ARDS und Therapie mit ECMO
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Use of ECMO in ARDS: does the EOLIA trial really help?
ECMO is associated with decreased hospital mortality in COVID-19 ARDS
Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
Mesenchymal stem cells-based therapies for severe ARDS with ECMO: a review
Influenza-A/H1N1-Infektion – Welchen Nutzen hat eine ECMO bei schwerem ARDS?
Optimierung der ECMO-Therapie bei schwerem ARDS
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
The initiation of adenovirus DNA replication
To prone or not to prone ARDS patients on ECMO
Hämolyse bei Patientinnen und Patienten mit ARDS und Therapie mit ECMO
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Use of ECMO in ARDS: does the EOLIA trial really help?
ECMO is associated with decreased hospital mortality in COVID-19 ARDS
Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
Mesenchymal stem cells-based therapies for severe ARDS with ECMO: a review